TY - JOUR
T1 - Screening for depression in children and adolescents
T2 - U.S. Preventive services task force recommendation statement
AU - U.S. Preventive Services Task Force
AU - Siu, Albert L.
AU - Bibbins-Domingo, Kirsten
AU - Grossman, David C.
AU - Baumann, Linda Ciofu
AU - Davidson, Karina W.
AU - Ebell, Mark
AU - García, Francisco A.R.
AU - Gillman, Matthew
AU - Herzstein, Jessica
AU - Kemper, Alex R.
AU - Krist, Alex H.
AU - Kurth, Ann E.
AU - Owens, Douglas K.
AU - Phillips, William R.
AU - Phipps, Maureen G.
AU - Pignone, Michael P.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).
AB - Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=84959308863&partnerID=8YFLogxK
U2 - 10.7326/M15-2957
DO - 10.7326/M15-2957
M3 - Review article
C2 - 26858097
AN - SCOPUS:84959308863
SN - 0003-4819
VL - 164
SP - 360
EP - 366
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 5
ER -